Generic Novelon ( Desogestrel and Ethinyl Estradiol )

Order cheap Generic Novelon (Desogestrel and Ethinyl Estradiol) without dr prescription in the United States

In our USA pharmacy, you can buy Novelon without a prescription, with delivery across the USA within 2‑5 days. Discreet and anonymous packaging.
Novelon (desogestrel and ethinyl estradiol) is a combined oral contraceptive pill containing a progestin (desogestrel) and an estrogen (ethinyl estradiol). It prevents pregnancy by suppressing ovulation, thickening cervical mucus to block sperm penetration, and altering the uterine lining to reduce the likelihood of implantation. The standard dose in each active tablet is 0.15 mg desogestrel and 0.03 mg ethinyl estradiol (note: the commonly marketed strength is 0.15/0.03 mg, not 0.15/0.3 mg; a dose of 0.3 mg ethinyl estradiol would be ten times the usual amount and is not standard in modern low‑dose pills).
Usual adult dose: Take one active tablet at the same time every day for 21 consecutive days, followed by a 7‑day tablet‑free interval (or 7 placebo tablets, depending on the specific product). Withdrawal bleeding typically occurs during the hormone‑free interval. Protection begins after 7 days of consistent use (if started on day 1 of the menstrual cycle, backup contraception is not needed).
Dosage form: Oral tablet, each active tablet contains 0.15 mg desogestrel and 0.03 mg ethinyl estradiol.
Onset of action: Contraceptive protection is immediate if started on the first day of menses; if started at any other time, use a non‑hormonal backup method for the first 7 days. Cycle control is established within the first month.
Duration of action: Each daily dose provides 24‑hour protection; sustained contraceptive effect relies on consistent daily intake. The pill is effective as long as it is taken correctly; fertility returns quickly after discontinuation.
Alcohol consumption in moderation does not reduce the contraceptive efficacy of the pill. However, heavy drinking may impair liver function and increase the risk of side effects, and vomiting or severe diarrhea within 3‑4 hours of taking a tablet may compromise absorption.
Most common side effects: breakthrough bleeding, spotting, nausea, breast tenderness, headache, mood changes, and weight gain. These are usually mild and diminish within the first 3 cycles.
Would you like to try Novelon without a prescription?

General Information about Novelon

• INN (International Nonproprietary Name): Desogestrel and ethinyl estradiol
• Brand names available in the USA: Novelon is not an FDA‑approved brand and is not marketed in the United States. Equivalent combination oral contraceptives with 0.15 mg desogestrel and 0.03 mg ethinyl estradiol are sold in the U.S. under brand names such as Desogen®, Ortho‑Cept®, Apri®, and their generics (e.g., Reclipsen®, Solia®).
• ATC code: G03AA09
• Dosage forms and strengths: Each active tablet contains 0.15 mg desogestrel and 0.03 mg ethinyl estradiol (standard low‑dose monophasic formulation). Inactive (placebo) tablets are included in some packages to complete a 28‑day cycle.
• Manufacturers in USA: Novelon is not manufactured in the USA. U.S.‑approved brands like Desogen are manufactured by Teva Pharmaceuticals USA, Inc. (Desogen) and by various generic producers (Apri by Teva, Ortho‑Cept by Janssen).
• Registration status in USA: Not approved by the U.S. Food and Drug Administration (FDA). Equivalent products (desogestrel 0.15 mg/EE 0.03 mg) are FDA‑approved.
• OTC / Rx classification: Prescription only (Rx).

Mechanism of Action and Pharmacology

Desogestrel is a third‑generation progestin derived from levonorgestrel. It is a prodrug that is rapidly metabolized to its active form, etonogestrel. Ethinyl estradiol is a synthetic estrogen. Together, they provide contraception through multiple mechanisms. The primary action is suppression of the hypothalamic‑pituitary‑ovarian axis: ethinyl estradiol and desogestrel/etonogestrel inhibit the secretion of gonadotropin‑releasing hormone (GnRH), thereby blocking the mid‑cycle surge of luteinizing hormone (LH) that triggers ovulation. The progestin component also thickens cervical mucus, creating a barrier to sperm migration, and alters endometrial receptivity to prevent implantation. After oral administration, both hormones are rapidly absorbed. Desogestrel undergoes extensive first‑pass hepatic metabolism to etonogestrel, which is approximately 98% protein‑bound. Ethinyl estradiol is primarily bound to albumin. Peak levels of etonogestrel occur about 1.5 hours after ingestion, and ethinyl estradiol peaks at 1‑2 hours. The elimination half‑life of etonogestrel is approximately 28 hours, and that of ethinyl estradiol is about 24 hours. Steady‑state levels are reached after about 5 days of daily dosing. The contraceptive effect is rapidly reversible upon discontinuation.

Indications

• Prevention of pregnancy in women of reproductive age.
• May also be used to regulate menstrual cycles, reduce dysmenorrhea, improve acne, or manage symptoms of polycystic ovary syndrome (off‑label).

Important Warnings and Precautions

Combined oral contraceptives (COCs) containing desogestrel and ethinyl estradiol are associated with an increased risk of venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism. This risk is higher in women who are obese, smoke, have a personal or family history of VTE, or are immobilised for long periods. The risk of VTE is slightly higher with desogestrel‑containing pills compared with levonorgestrel‑containing pills. Cigarette smoking, especially in women over 35, greatly increases the risk of serious cardiovascular events, including myocardial infarction, stroke, and vascular death. These pills are contraindicated in women over 35 who smoke. Liver tumors, both benign and malignant, have been reported; discontinue the pill if severe upper abdominal pain or signs of intra‑abdominal hemorrhage develop. Hypertension may occur; blood pressure should be monitored before and during use. Gallbladder disease, cholestatic jaundice, and worsening of depression have also been reported. The pill does not protect against HIV or other sexually transmitted infections. Ocular lesions such as retinal thrombosis have been associated with COC use; any unexplained visual loss or proptosis requires immediate drug cessation and evaluation.

At‑risk groups

• Elderly: Not indicated for postmenopausal women; COCs are prescribed to women of reproductive age.
• Pregnancy: Contraindicated. Discontinue immediately if pregnancy is confirmed. There is no evidence of an increased risk of birth defects in women who inadvertently used COCs during early pregnancy.
• Breastfeeding: COCs may decrease milk production and alter milk composition; they are not recommended for nursing mothers until the infant is fully weaned or at least 6 months old, depending on clinical judgment. Small amounts of hormones are excreted in milk but have not been shown to harm the infant.
• Renal impairment: Use with caution; fluid retention may be exacerbated. No specific dose adjustment is necessary.
• Hepatic impairment: Contraindicated in patients with acute or chronic liver disease, including hepatic tumors, or a history of cholestatic jaundice of pregnancy or with prior pill use. Liver function must return to normal before initiating the pill.
• Pediatric: Safety and efficacy have been established in adolescent females; dosing is the same as in adults. Use before menarche is not indicated.
• Cardiovascular risk: Contraindicated in patients with a history of VTE, thrombophilia, stroke, coronary artery disease, uncontrolled hypertension, complicated valvular heart disease, or migraine with aura.

Driving and alcohol

Novelon is not known to impair the ability to drive or operate machinery. Alcohol intake does not reduce contraceptive efficacy; however, heavy drinking can lead to liver damage, which may affect hormone metabolism, and increases the risk of missing doses due to intoxication. Women who experience vomiting or severe diarrhea within 3‑4 hours of taking a tablet should follow the instructions for missed pills and use backup contraception.

Dosage Instructions

• Standard 21‑day regimen: Take one active tablet daily for 21 consecutive days, then stop for 7 days. Withdrawal bleeding usually starts 2‑4 days after the last active tablet. Restart the next 21‑day cycle on the 8th day even if bleeding continues.
• 28‑day pack (with 7 placebo tablets): Take one active tablet daily for 21 days, followed by one inert tablet daily for 7 days. Do not skip days between packs.
• Starting the first cycle: Take the first tablet on the first day of menstrual bleeding (Day 1 start). No backup contraceptive is needed. Alternatively, a Sunday start is possible, but a backup non‑hormonal method should be used for the first 7 days.
• Administration: Take the tablet at the same time each day, with or without food. Swallow whole with a glass of water. To minimize nausea, it may be taken at bedtime.
• Missed dose: If one active tablet is missed by less than 24 hours, take it as soon as remembered and continue as normal (backup not required). If two or more tablets are missed, take the most recent missed tablet as soon as possible, discard the earlier missed ones, and use a backup method for the next 7 days. If the missed tablets occurred in the third week, skip the placebo week and go directly to the next pack. Refer to the product leaflet or a clinician for detailed instructions.
• Protection after illness: If severe vomiting or diarrhea occurs within 3‑4 hours of taking an active tablet, treat it as a missed dose and use backup contraception.

Side Effects and Contraindications

Most common side effects: Breakthrough bleeding or spotting (especially in the first cycles), nausea, vomiting, breast tenderness or enlargement, headache, migraine, mood swings, depression, decreased libido, and fluid retention/weight gain. These often resolve after the third cycle.
Serious adverse reactions: Venous thromboembolism (deep vein thrombosis, pulmonary embolism) with an incidence of approximately 3‑9 per 10,000 woman‑years; myocardial infarction, stroke, hypertension, liver tumors (hepatic adenoma, hepatocellular carcinoma), gallbladder disease, pancreatitis, and severe depression. Chloasma (skin discoloration) may persist. Contact lenses may become intolerant due to changes in corneal curvature.
Absolute contraindications: Current or past history of venous or arterial thrombotic/thromboembolic events (e.g., DVT, PE, stroke, MI); thrombophilia; migraine with aura; diabetes mellitus with vascular complications; uncontrolled hypertension; active liver disease or liver tumors; known or suspected estrogen‑dependent malignancies (e.g., breast, endometrial); undiagnosed abnormal uterine bleeding; pregnancy; and smoking in women over 35 years of age.

Drug Interactions

• Enzyme‑inducing drugs (e.g., rifampicin, rifabutin, phenytoin, carbamazepine, topiramate, barbiturates, modafinil, St. John's Wort): May increase hepatic metabolism of contraceptive hormones and reduce efficacy. Use a barrier method for the duration of treatment and for 28 days after discontinuation of the inducer.
• Protease inhibitors and some antiretrovirals (e.g., ritonavir, nelfinavir, efavirenz): Can increase or decrease hormone levels; consult HIV treatment guidelines and use backup contraception.
• Broad‑spectrum antibiotics (except rifampicin‑like drugs): Routine antibiotic use (e.g., amoxicillin, tetracycline) does not generally compromise contraceptive efficacy. However, individual product labeling may suggest caution; a backup method is not routinely required unless the antibiotic causes vomiting or diarrhea.
• Griseofulvin: May decrease contraceptive efficacy; use additional barrier protection.
• Cyclosporine, theophylline, corticosteroids: Ethinyl estradiol may inhibit hepatic metabolism of these drugs, increasing their toxicity. Monitor drug levels and clinical response.
• Lamotrigine: COCs may decrease lamotrigine levels, potentially reducing seizure control; adjust lamotrigine dose upon initiation and discontinuation of the pill.
• Alcohol: No pharmacokinetic interaction, but heavy drinking increases the risk of missing pills and liver stress.

Practical Advice

• Take Novelon at the same time every day to maintain stable hormone levels and optimal efficacy. Use a phone alarm if needed.
• If you experience nausea, take the pill with a meal or at bedtime.
• Report any severe leg pain or swelling, sudden shortness of breath, chest pain, severe headache, vision changes, or numbness/weakness on one side of the body immediately — these could be signs of a blood clot or stroke.
• Do not smoke while taking this medication, especially if you are over 35.
• Store at room temperature, away from light and moisture. Keep out of reach of children and pets.
• Use a backup non‑hormonal contraceptive for the first 7 days if starting the pill for the first time or after certain drug interactions.
• If you miss a withdrawal bleed and could have been pregnant, take a pregnancy test before starting the next pack.
• Annual check‑ups including blood pressure, breast and pelvic exams, and Pap smears are recommended.

Alternative Medications

• Other combined oral contraceptives: Pills containing levonorgestrel (e.g., Alesse, Aviane) have a slightly lower VTE risk but similar efficacy. Norgestimate‑containing pills (e.g., Ortho Tri‑Cyclen) are also widely used.
• Progestin‑only pill (mini‑pill): Norethindrone or drospirenone‑only pills are suitable for women who cannot take estrogen, such as those who are breastfeeding or have a history of VTE.
• Long‑acting reversible contraceptives (LARCs): The etonogestrel implant (Nexplanon), levonorgestrel intrauterine system (Mirena, Kyleena), and copper IUD (Paragard) provide years of highly effective, reversible contraception without daily pill‑taking.
• Contraceptive patch (Xulane) and vaginal ring (NuvaRing): Combined hormonal methods that require weekly or monthly attention.
• Non‑hormonal methods: Condoms, diaphragm, cervical cap, fertility awareness, and sterilization.

Clinical Efficacy

When taken correctly and consistently, combined oral contraceptives containing desogestrel 0.15 mg and ethinyl estradiol 0.03 mg have a first‑year failure rate of approximately 0.1‑0.5%, making them among the most effective reversible contraceptive methods. However, typical‑use failure rates, which account for missed pills, are about 5‑9%. The contraceptive action is rapidly reversible; ovulation returns within weeks of stopping the pill. In addition to pregnancy prevention, these pills offer cycle control, reduced dysmenorrhea, and a lower risk of endometrial and ovarian cancer with long‑term use. The desogestrel/EE combination provides good androgenic side‑effect profiles, often improving acne. The slightly elevated VTE risk compared to levonorgestrel pills must be weighed against individual cardiovascular risk factors.

Important:

Novelon (desogestrel 0.15 mg / ethinyl estradiol 0.03 mg) is a combined oral contraceptive that must be used under the supervision of a healthcare provider. It is not FDA‑approved in the United States; equivalent pills are available under different brand names. This pill does not protect against HIV or other sexually transmitted infections. It is contraindicated in women who smoke and are over 35 years old, and in those with a history of blood clots, stroke, heart attack, liver disease, or certain cancers. Seek immediate medical attention for signs of a blood clot: severe leg pain/swelling, sudden chest pain or shortness of breath, sudden severe headache, vision changes, or numbness/weakness on one side. The risk of blood clots is slightly higher with desogestrel‑containing pills than with some other progestins. If you miss two or more tablets, use a backup method and consult the package insert or your doctor. Do not use this medication if you are pregnant or breastfeeding without medical advice. Keep out of reach of children. The information provided is not a substitute for professional medical advice, diagnosis, or treatment.

How to buy Generic Novelon no prescription U.S. Online Pharmacy